David Setboun
Chief Operating Officer @Alkeus Pharmaceuticals, Inc
Signup · Get unlimited contacts
WORK HISTORY
Chief Operating Officer @Alkeus Pharmaceuticals, Inc
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease. Additional information can be found on the company’s website at
EDUCATION
Ivey Business School at Western University
MBA Exchange Program, Entrepreneurship
Harvard Business School
AMP
HEC Paris
MBA, International Business
Paris-Sud University (Paris XI)
Doctor of Pharmacy (Pharm.D.), Pharmacy
Massachusetts Institute of Technology
Leading Entreprise Transformation Program, Business Administration and Management, General
SKILLS
ABOUT DAVID SETBOUN
Pharmaceutical C executive in charge of corporate development, strategy and commercial…
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.